Core Viewpoint - The inclusion of the product Methylphenidate Hydrochloride Extended-Release Capsules in the National Medical Insurance Directory is expected to positively impact the company's market promotion and sales performance [3]. Group 1: Product Inclusion in Medical Insurance - The product Methylphenidate Hydrochloride Extended-Release Capsules has been included in the National Medical Insurance Directory for 2025, with the agreement period allowing for Class B payment [1]. - The application price for the product remains confidential, and the payment standard is marked as * [1]. Group 2: Sales Performance - The product received approval from the National Medical Products Administration on January 8, 2025, and generated sales revenue of RMB 12.4 million in the first three quarters of 2025 [2]. - Following the acquisition of a 53.28% stake in Henan Zhongshuai Pharmaceutical Technology Co., Ltd. in August 2025, the sales revenue from this product accounted for approximately 0.15% of the company's total revenue for the same period [2]. Group 3: Impact on Company Performance - The inclusion of the product in the National Medical Insurance Directory is anticipated to enhance market promotion and sales, positively affecting the company's operational performance [3]. - The implementation of the National Medical Insurance Directory is set for January 1, 2026, and is not expected to have a significant impact on the current year's operational performance [3].

截至12月8日收盘，青蒿素概念下跌0.51%，位居概念板块跌幅榜前列，板块内，德龙汇能、百花医 药、新和成等跌幅居前。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 共封装光学(CPO) | 4.72 | 天津自贸区 | -0.99 | | F5G概念 | 4.30 | 草甘膦 | -0.86 | | 光纤概念 | 3.67 | 青蒿素 | -0.51 | | 铜缆高速连接 | 3.57 | 煤炭概念 | -0.51 | | 福建自贸区 | 3.44 | 高股息精选 | -0.38 | | PET铜箔 | 3.02 | 超级品牌 | -0.34 | | 海南自贸区 | 3.00 | 金属锌 | -0.32 | | WiFi 6 | 3.00 | 大豆 | -0.31 | | 光刻机 | 3.00 | 啤酒概念 | -0.31 | | 海峡两岸 | 2.98 | 共享单车 | -0.29 | 资金面上看，今日青蒿素概念板块获主力资金净流出0.62亿元，其中，5股获主力资金净流出，净流出 资金居首的是德龙汇能， ...

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its subsidiary Henan Zhongshuai Pharmaceutical Co., Ltd. has successfully negotiated the inclusion of its product, methylphenidate hydrochloride sustained-release capsules, into the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) [1] Group 1 - The product will be reimbursed under Category B during the agreement period [1]

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its subsidiary Henan Zhongshuai Pharmaceutical Co., Ltd. has successfully negotiated the inclusion of its product, methylphenidate hydrochloride sustained-release capsules, into the National Medical Insurance Directory for 2025, under the category of Class B payment [1] Group 1 - The product is indicated for attention deficit hyperactivity disorder (ADHD) and cognitive enhancement [1] - The negotiation allows for the product to be reimbursed under the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance [1] - The agreement period for the negotiated drug is specified, indicating a structured approach to pricing and reimbursement [1]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-106 华润双鹤药业股份有限公司 关于公司药品新进国家医保目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 根据国家医保局、人力资源社会保障部发布的《关于印发<国家 基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创 新药品目录>(2025 年)的通知》，华润双鹤药业股份有限公司(以下简 称"公司")控股公司河南中帅药业有限公司(控股子公司河南中帅医 药科技有限责任公司之全资子公司)的产品盐酸右哌甲酯缓释胶囊通 过医保谈判纳入《国家基本医疗保险、生育保险和工伤保险药品目录 (2025 年)》(以下简称"《国家医保目录》")，协议期内谈判药品按 照乙类支付。现将相关信息公告如下： 一、产品进入医保情况 | 限定支付范围 | 限 6 | 岁及 | 6 | 岁以上注意缺陷多动障碍(ADHD) | | | | --- | --- | --- | --- | --- | --- | --- | | 协议有效期 | 2026 | 年 1 | 月 1 ...

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. announced that its product, methylphenidate hydrochloride sustained-release capsules, has been included in the National Medical Insurance Directory for 2025, which will positively impact the company's market promotion and sales [1] Group 1: Product Information - The product included is methylphenidate hydrochloride sustained-release capsules, classified under code XN06B, used for treating Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and above [1] - The inclusion in the National Medical Insurance Directory means that the product will be reimbursed under Category B during the agreement period [1] Group 2: Market Impact - The inclusion of the product in the National Medical Insurance Directory is expected to enhance market promotion and sales, leading to a positive impact on the company's operating performance [1] - The new National Medical Insurance Directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's performance for the current fiscal year [1]

Group 1: Major Transactions - Bohai Chemical is planning to sell 100% equity of Tianjin Bohai Petrochemical and acquire control of Anhui Taida New Materials through a combination of share issuance and cash payment, leading to a significant asset restructuring [1] - Zhongneng Electric is set to acquire 65% equity and debt from three companies, which may constitute a major asset restructuring but will not involve share issuance or change in control [4] - Hai Tai Development has decided to terminate the acquisition of controlling interest in Zhixueyun Technology due to disagreements on key terms, ensuring no adverse impact on normal business operations [5] Group 2: Performance Updates - Wen's shares reported a sales revenue of 3.324 billion yuan from meat chickens in November, marking a year-on-year increase of 10.18% [6] - Shuguang shares saw a 71.07% year-on-year increase in vehicle sales, totaling 207 units in November [6] - Muyuan shares experienced a decline in sales revenue from commodity pigs, reporting 9.39 billion yuan, a decrease of 20.43% year-on-year [6] - Pengding Holdings reported a 5.58% year-on-year decrease in consolidated revenue for November [6] Group 3: Industry Developments - Xiangxi Dairy reported a 6.3% month-on-month increase in fresh milk production in November, although it saw a year-on-year decline of 6.47% [7] - Baisheng Intelligent plans to acquire 51% equity in Zhongke Shengu, which focuses on the research and application of core technologies for embodied intelligent robots [7]

华润双鹤药业股份有限公司 关于全资孙公司秦皇岛紫竹药业有限公司 通过GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-105 近日，华润双鹤药业股份有限公司(以下简称"公司")全资孙公司 秦皇岛紫竹药业有限公司(以下简称"秦皇岛紫竹")收到河北省药品监 督管理局颁发的雌三醇原料药《药品 GMP 符合性检查告知书》[编号： 冀药监化药符(2025)151 号]，现将相关情况公告如下： 结论：符合要求 本次检查是雌三醇原料药上市前的首次药品 GMP 符合性检查。 该检查项目是在原有厂房、设备情况下的检查，未投入资金。 二、本次检查所涉生产线及产品情况 生产车间生产线：多功能车间生产线 10 一、GMP 检查相关信息 被检查单位名称：秦皇岛紫竹药业有限公司 检查地址：河北省秦皇岛市经济技术开发区龙海道 10 号 检查范围及相关车间、生产线：原料药(雌三醇，多功能车间生 产线 10) 检查时间：2025 年 10 月 23 日-2025 年 1 ...

公司本次通过药品GMP符合性检查，表明公司产品生产质量管理符合GMP要求，将有利于公司继续保 持稳定的产品质量和持续稳定的生产能力，以满足相关药品的市场需求。 华润双鹤（600062）(600062.SH)发布公告，近日，公司全资孙公司秦皇岛紫竹药业有限公司(简称"秦皇 岛紫竹")收到河北省药品监督管理局颁发的雌三醇原料药《药品GMP符合性检查告知书》[编号：冀药 监化药符(2025)151号]。检查范围及相关车间、生产线：原料药(雌三醇，多功能车间生产线10)。 ...

华润双鹤(600062.SH)公告称，全资孙公司秦皇岛紫竹药业有限公司收到河北省药品监督管理局颁发的 雌三醇原料药《药品GMP符合性检查告知书》。此次检查是雌三醇原料药上市前的首次药品GMP符合 性检查，未投入资金。公司通过此次检查，表明产品生产质量管理符合GMP要求，有利于继续保持稳 定的产品质量和持续稳定的生产能力，但不会对公司业绩产生重大影响。医药产品销售受政策、市场环 境等因素影响，存在不确定性。 ...